<b><a href="myelostat.htm" class="texte">About Myelostat (homoharringtonine) Stragen.</a></b> <br> <br> <a href="myelostat.htm">Homoharringtonine</a> is known since years for its activity in the treatment of<br> myeloid leukemia. In the USA, the National Cancer Institute dedicated a wide<br> development program to this molecule, using a natural extract from<br> Cephalotaxus sp. This natural formulation did not allow a satisfactory<br> reproducibility in batches manufactory, with variations in purity profile<br> and issues for the raw material supply.<br> Stragen Pharma has developed a patented hemi-synthetic formulation of<br> homoharringtonine by direct attachment of chiral side chain. This<br> hemi-synthetic formulation avoids any manufacturing issues.<br> The mechanism of action of homoharringtonine is mainly based on the<br> inhibition of protein synthesis (telomerase, survivin,VEGF, MCL1∑) and the<br> activation of the cell apoptosis (natural death of the cell) in a time and<br> dose dependant manner.<br> This mechanism of action not only leads to a clinically relevant efficacy<br> level, with a low related toxicity but also offers a variety of possible<br> combination with other drugs without cross resistance and with proven<br> potentializing effect.
About Stragen
|
Contact
|
Sitemap
|
Legal Notices
© 2005
Stragen
Pharma SA - All rights reserved
